BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 14558057)

  • 1. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.
    Proven A; Gabriel SE; Orces C; O'Fallon WM; Hunder GG
    Arthritis Rheum; 2003 Oct; 49(5):703-8. PubMed ID: 14558057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study.
    Salvarani C; Hunder GG
    Arthritis Rheum; 2001 Apr; 45(2):140-5. PubMed ID: 11324777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of oral cyclophosphamide in the treatment of giant cell arteritis.
    Quartuccio L; Maset M; De Maglio G; Pontarini E; Fabris M; Mansutti E; Mariuzzi L; Pizzolitto S; Beltrami CA; De Vita S
    Rheumatology (Oxford); 2012 Sep; 51(9):1677-86. PubMed ID: 22627726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.
    García-Martínez A; Hernández-Rodríguez J; Espígol-Frigolé G; Prieto-González S; Butjosa M; Segarra M; Lozano E; Cid MC
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):835-41. PubMed ID: 20535794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis.
    Narváez J; Nolla-Solé JM; Clavaguera MT; Valverde-García J; Roig-Escofet D
    J Rheumatol; 1999 Sep; 26(9):1945-52. PubMed ID: 10493675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course.
    Liozon E; Boutros-Toni F; Ly K; Loustaud-Ratti V; Soria P; Vidal E
    J Rheumatol; 2003 Jun; 30(6):1272-6. PubMed ID: 12784402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients.
    Chevalet P; Barrier JH; Pottier P; Magadur-Joly G; Pottier MA; Hamidou M; Planchon B; El Kouri D; Connan L; Dupond JL; De Wazieres B; Dien G; Duhamel E; Grosbois B; Jego P; Le Strat A; Capdeville J; Letellier P; Agron L
    J Rheumatol; 2000 Jun; 27(6):1484-91. PubMed ID: 10852275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity.
    Weyand CM; Fulbright JW; Hunder GG; Evans JM; Goronzy JJ
    Arthritis Rheum; 2000 May; 43(5):1041-8. PubMed ID: 10817557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.
    Nesher G; Berkun Y; Mates M; Baras M; Rubinow A; Sonnenblick M
    Arthritis Rheum; 2004 Apr; 50(4):1332-7. PubMed ID: 15077317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
    Mahr AD; Jover JA; Spiera RF; Hernández-García C; Fernández-Gutiérrez B; Lavalley MP; Merkel PA
    Arthritis Rheum; 2007 Aug; 56(8):2789-97. PubMed ID: 17665429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical course of Horton disease. Apropos of 42 cured patients].
    Liozon F; Vidal E; Boutros-Toni F; Gaches F; Loustaud-Ratti V; Liozon E; Berdah JF
    Ann Med Interne (Paris); 1994; 145(4):223-9. PubMed ID: 8092645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
    Alba MA; García-Martínez A; Prieto-González S; Espígol-Frigolé G; Butjosa M; Tavera-Bahillo I; Rodríguez-Pintó I; Hernández-Rodríguez J; Cid MC
    Semin Arthritis Rheum; 2014 Jun; 43(6):772-7. PubMed ID: 24315461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion.
    Fardet L; Flahault A; Kettaneh A; Tiev KP; Généreau T; Tolédano C; Lebbé C; Cabane J
    Br J Dermatol; 2007 Jul; 157(1):142-8. PubMed ID: 17501951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of corticosteroid therapy in giant cell arteritis.
    Fernandez-Herlihy L
    J Rheumatol; 1980; 7(3):361-4. PubMed ID: 6772784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.
    Hoffman GS; Merkel PA; Brasington RD; Lenschow DJ; Liang P
    Arthritis Rheum; 2004 Jul; 50(7):2296-304. PubMed ID: 15248230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.
    Labarca C; Koster MJ; Crowson CS; Makol A; Ytterberg SR; Matteson EL; Warrington KJ
    Rheumatology (Oxford); 2016 Feb; 55(2):347-56. PubMed ID: 26385368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis.
    Salvarani C; Cimino L; Macchioni P; Consonni D; Cantini F; Bajocchi G; Pipitone N; Catanoso MG; Boiardi L
    Arthritis Rheum; 2005 Apr; 53(2):293-7. PubMed ID: 15818722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.
    Martínez-Taboada VM; Rodríguez-Valverde V; Carreño L; López-Longo J; Figueroa M; Belzunegui J; Mola EM; Bonilla G
    Ann Rheum Dis; 2008 May; 67(5):625-30. PubMed ID: 18086726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality.
    González-Gay MA; Blanco R; Abraira V; García-Porrúa C; Ibáñez D; García-Pais MJ; Rigueiro MT; Sánchez-Andrade A; Guerrero J; Casariego E
    J Rheumatol; 1997 Nov; 24(11):2171-6. PubMed ID: 9375880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.